|
Published by: Global Markets Direct
Published: Nov. 28, 2012 - 43 Pages
Table of Contents- Introduction
- Global Markets Direct Report Coverage
- Herpes Labialis (Oral Herpes) Overview
- Therapeutics Development
- An Overview of Pipeline Products for Herpes Labialis (Oral Herpes)
- Herpes Labialis (Oral Herpes) Therapeutics under Development by Companies
- Late Stage Products
- Comparative Analysis
- Mid Clinical Stage Products
- Comparative Analysis
- Early Clinical Stage Products
- Comparative Analysis
- Herpes Labialis (Oral Herpes) Therapeutics – Products under Development by Companies
- Companies Involved in Herpes Labialis (Oral Herpes) Therapeutics Development
- BioAlliance Pharma SA
- Nitric Biotherapeutics, Inc.
- NanoBio Corporation
- Redox Pharmaceutical Corporation
- Beech Tree Labs, Inc.
- EMS S.A.
- Herpes Labialis (Oral Herpes) – Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Route of Administration
- Assessment by Molecule Type
- Drug Profiles
- acyclovir - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- doxorubicin - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- NB-001 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- BTL-TML-HSV - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- acyclovir - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- penciclovir - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Herpes Labialis (Oral Herpes) Therapeutics – Drug Profile Updates
- Herpes Labialis (Oral Herpes) Therapeutics - Dormant Products
- Herpes Labialis (Oral Herpes) – Product Development Milestones
- Featured News & Press Releases
- Jul 26, 2012: BioAlliance Pharma Receives US Patent Covering Sitavig
- May 29, 2012: BioAlliance Announces Receivability Of Sitavig US Registration Dossier
- Oct 05, 2011: BioAlliance Submits Sitavir European Registration Dossier Through European Decentralized Procedure
- May 11, 2011: NanoBio And GSK Commence Phase III Studies Of Nanoemulsion-based OTC Treatment For Cold Sores
- Feb 07, 2011: BioAlliance Pharma Presents Results Of International Survey Performed With Nielsen In Patients Suffering From Herpes Labialis
- Nov 17, 2010: BioAlliance Pharma Presents Pharmacokinetic Results Of Sitavir At AAPS Annual Meeting
- Nov 05, 2010: AiCuris To Present Preclinical And Phase I Data Of Anti-HSV Drug AIC316 At Antivirals Congress
- Sep 14, 2010: Beech Tree Labs Initiates Phase I/IIa Oral Herpes Trial
- Sep 07, 2010: BioAlliance Pharma Receives European Patent For Acyclovir Lauriad
- Aug 26, 2010: BioAlliance Pharma Plans To Submit Acyclovir Lauriad NDA
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- List of Tables
- Number of Products Under Development for Herpes Labialis (Oral Herpes), H2 2012
- Products under Development for Herpes Labialis (Oral Herpes) – Comparative Analysis, H2 2012
- Number of Products under Development by Companies, H2 2012
- Comparative Analysis by Late Stage Development, H2 2012
- Comparative Analysis by Mid Clinical Stage Development, H2 2012
- Comparative Analysis by Early Clinical Stage Development, H2 2012
- Products under Development by Companies, H2 2012
- BioAlliance Pharma SA, H2 2012
- Nitric Biotherapeutics, Inc., H2 2012
- NanoBio Corporation, H2 2012
- Redox Pharmaceutical Corporation, H2 2012
- Beech Tree Labs, Inc., H2 2012
- EMS S.A., H2 2012
- Assessment by Monotherapy Products, H2 2012
- Assessment by Stage and Route of Administration, H2 2012
- Assessment by Stage and Molecule Type, H2 2012
- Herpes Labialis (Oral Herpes) Therapeutics – Drug Profile Updates
- Herpes Labialis (Oral Herpes) Therapeutics – Dormant Products
- List of Figures
- Number of Products under Development for Herpes Labialis (Oral Herpes), H2 2012
- Products under Development for Herpes Labialis (Oral Herpes) – Comparative Analysis, H2 2012
- Products under Development by Companies, H2 2012
- Late Stage Products, H2 2012
- Mid Clinical Stage Products, H2 2012
- Early Clinical Stage Products, H2 2012
- Assessment by Monotherapy Products, H2 2012
- Assessment by Route of Administration, H2 2012
- Assessment by Stage and Route of Administration, H2 2012
- Assessment by Molecule Type, H2 2012
- Assessment by Stage and Molecule Type, H2 2012
AbstractHerpes Labialis (Oral Herpes) – Pipeline Review, H2 2012
Summary
Global Markets Direct’s, 'Herpes Labialis (Oral Herpes) - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Herpes Labialis (Oral Herpes), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Herpes Labialis (Oral Herpes). Herpes Labialis (Oral Herpes) - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope- A snapshot of the global therapeutic scenario for Herpes Labialis (Oral Herpes).
- A review of the Herpes Labialis (Oral Herpes) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Herpes Labialis (Oral Herpes) pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy- Identify and understand important and diverse types of therapeutics under development for Herpes Labialis (Oral Herpes).
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Herpes Labialis (Oral Herpes) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Get full details about this report >>
|
US: 800.298.5699
Int'l: +1.240.747.3093
|
|
|
About MarketResearch.com
MarketResearch.com is an online aggregator selling over 400,000 market research reports,
company profiles and country profiles from over 720 research firms. Our reports will
provide you with the critical business and competitive intelligence you need for strategic planning and marketing
research. Coverage includes the US, UK, Europe, Asia and global markets.
|
